| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9327383 | Gynecologic Oncology | 2005 | 6 Pages |
Abstract
The combination of paclitaxel and carboplatin with amifostine was well reasonably tolerated in this cohort. The regimen demonstrated significant activity in endometrial cancer, comparable to other multi-agent chemotherapy programs in terms of response rate and survival, and with a favorable toxicity profile.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Sidney A. Scudder, P.Y. Liu, Sharon P. Wilczynski, Harriet O. Smith, Caroline Jiang, Alton V. III, Gregory B. Smith, Edward V. Hannigan, Maurie Markman, David S. Alberts,